The estimated Net Worth of Martin Sebastian Olivo is at least $24.4 Thousand dollars as of 10 June 2021. Dr Olivo owns over 9,893 units of Protara Therapeutics Inc stock worth over $24,385 and over the last 4 years he sold TARA stock worth over $0.
Dr has made over 1 trades of the Protara Therapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 9,893 units of TARA stock worth $99,919 on 10 June 2021.
The largest trade he's ever made was buying 9,893 units of Protara Therapeutics Inc stock on 10 June 2021 worth over $99,919. On average, Dr trades about 4,947 units every 0 days since 2021. As of 10 June 2021 he still owns at least 14,344 units of Protara Therapeutics Inc stock.
You can see the complete history of Dr Olivo stock trades at the bottom of the page.
Dr. Martin Sebastian Olivo M.D. is the Chief Medical Officer at Protara Therapeutics Inc.
Dr D is 44, he's been the Chief Medical Officer of Protara Therapeutics Inc since . There are 10 older and 3 younger executives at Protara Therapeutics Inc. The oldest executive at Protara Therapeutics Inc is Roger Garceau, 66, who is the Independent Director.
Martin's mailing address filed with the SEC is C/O PROTARA THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 3RD FLOOR, NEW YORK, NY, 10010.
Over the last 5 years, insiders at Protara Therapeutics Inc have traded over $3,287,540 worth of Protara Therapeutics Inc stock and bought 250,034 units worth $1,947,929 . The most active insiders traders include Management Inc. Opaleye, Richard S Levy, and Gregory Sargen. On average, Protara Therapeutics Inc executives and independent directors trade stock every 35 days with the average trade being worth of $34,731. The most recent stock trade was executed by Management Inc. Opaleye on 9 September 2024, trading 61,992 units of TARA stock currently worth $114,065.
protara therapeutics, inc., a clinical-stage company, engages in the identifying and advancing transformative therapies for people with rare and specialty diseases. the company's lead program is tara-002, an investigational cell therapy for the treatment of lymphatic malformations. it also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. the company was formerly known as artara therapeutics, inc. and changed its name to protara therapeutics, inc. in may 2020. protara therapeutics, inc. is based in new york, new york.
Protara Therapeutics Inc executives and other stock owners filed with the SEC include: